EUVIMEDEUVIMED entdecken
Crossref

Repurposing FDA‐Approved Drugs as Acetylcholinesterase Inhibitors for Alzheimer's Disease: An Integrated In Silico Approach

Amarjith Thiyyar Kandy, Thirumoorthy Durai Ananda Kumar, Divakar Selvaraj, Srikanth Jupudi

ChemistrySelect · 2026-06 · 11 (24)

DOI: 10.1002/slct.202506836 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 22.06.2026. Verfasst von Amarjith Thiyyar Kandy und 3 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Indian Council of Medical Research.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline and memory loss. Current therapies offer limited symptomatic relief and are often associated with adverse effects, necessitating the identification of safer and more effective molecules. In this study, an integrated computational approach involving e‐pharmacophore modelling, molecular mechanics, DFT analysis, and dynamics simulations were employed to identify acetylcholinesterase (AChE) inhibitors from FDA‐approved drugs. An e‐pharmacophore model (AHHRR) was generated using the AChE–Donepezil complex (PDB ID: 6O4W), and a library of 1123 FDA‐approved drugs were screened against the model. The top 30 hits were shortlisted, followed by docking analysis, which identified 10 promising candidates with Glide scores ranging from −13.92 to −12.02 kcal/mol. Among these, Ropinirole demonstrated significant binding affinity with a Glide score of −13.31 kcal/mol and a Δ G _bind of −93.72 kcal/mol, along with superior ligand efficiency compared to standard Donepezil. Key interactions of Ropinirole with residues TRP86, TYR337, PHE338, TRP286, and TYR341 suggest a binding mode similar to Donepezil. DFT studies confirmed its favorable electronic properties. Dynamics simulations demonstrated robust and stable binding of Ropinirole to the AChE active site throughout 200 ns. These findings highlight Ropinirole as a promising candidate for designing novel molecules for treating Alzheimer's disease.

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Kandy, A. T., Kumar, T. D. A., Selvaraj, D., & Jupudi, S. (2026). Repurposing FDA‐Approved Drugs as Acetylcholinesterase Inhibitors for Alzheimer's Disease: An Integrated In Silico Approach. ChemistrySelect, 11(24). https://doi.org/10.1002/slct.202506836

Vancouver

Kandy AT, Kumar TDA, Selvaraj D, Jupudi S. Repurposing FDA‐Approved Drugs as Acetylcholinesterase Inhibitors for Alzheimer's Disease: An Integrated In Silico Approach. ChemistrySelect. 2026;11(24). doi:10.1002/slct.202506836

BibTeX
@article{Kandy2026,
  author = {Kandy, Amarjith Thiyyar and Kumar, Thirumoorthy Durai Ananda and Selvaraj, Divakar and Jupudi, Srikanth},
  title = {Repurposing FDA‐Approved Drugs as Acetylcholinesterase Inhibitors for Alzheimer's Disease: An Integrated In Silico Approach},
  journal = {ChemistrySelect},
  year = {2026},
  volume = {11},
  number = {24},
  doi = {10.1002/slct.202506836}
}
Kostenlos starten →